Una nueva vacuna antineumocócica conjugada VAX-24 mejora la inmunogenicidad de los polisacáridos capsulares sin supresión epitópica
Wassil J, Sisti M, Fairman J et al. Evaluating the safety, tolerability, and immunogenicity of a 24-valent pneumococcal conjugate vaccine (VAX-24) in healthy adults aged 18 to 64 years: a phase 1/2, double-masked, dose-finding, active-controlled, randomised clinical trial. Lancet Infect Dis published on line December 4, 2023 https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00572-8/fulltext Fae II/II de un ensayo clínico aleatorio,…
Detalles